Bio Medica Laboratories Limited (NSE:BMLL)
India · Delayed Price · Currency is INR 141.45
+2.75 (1.98%)
At close: Jul 27, 2026
Bio Medica Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 430.9 | 381.95 | 152.49 | 162.28 | 212.25 |
Other Revenue | 0.23 | - | - | - | - |
| 431.13 | 381.95 | 152.49 | 162.28 | 212.25 | |
Revenue Growth | 12.88% | 150.47% | -6.03% | -23.54% | 64.21% |
Cost of Revenue | 174.83 | 203.23 | 67.42 | 115.7 | 167.8 |
Gross Profit | 256.3 | 178.72 | 85.07 | 46.58 | 44.45 |
Selling, General & Admin | 30.51 | 19.57 | 17.03 | 18.12 | 17.27 |
Other Operating Expenses | 29.06 | 4.18 | 11.66 | 11.35 | 8.26 |
Operating Expenses | 71.2 | 33.81 | 39.8 | 34.44 | 28.8 |
Operating Income | 185.1 | 144.92 | 45.28 | 12.14 | 15.65 |
Interest Expense | -22.56 | -13.28 | -9.38 | -7.3 | -7.68 |
Interest & Investment Income | - | 0.02 | 0.08 | 0.21 | - |
Currency Exchange Gain (Loss) | - | 0.03 | - | -0 | - |
Other Non Operating Income (Expenses) | - | -0.27 | -0.28 | -0.45 | -0 |
EBT Excluding Unusual Items | 162.54 | 131.43 | 35.7 | 4.6 | 7.97 |
Pretax Income | 162.54 | 131.43 | 35.7 | 4.88 | 7.97 |
Income Tax Expense | 43.67 | 33.48 | 9.38 | 1.28 | 2.08 |
Earnings From Continuing Operations | 118.88 | 97.95 | 26.31 | 3.6 | 5.89 |
Minority Interest in Earnings | -1.07 | - | - | - | - |
Net Income | 117.81 | 97.95 | 26.31 | 3.6 | 5.89 |
Net Income to Common | 117.81 | 97.95 | 26.31 | 3.6 | 5.89 |
Net Income Growth | 20.27% | 272.24% | 631.22% | -38.90% | 34.10% |
Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 |
Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 |
Shares Change | -0.90% | -0.00% | - | -0.00% | 0.00% |
EPS (Basic) | 12.95 | 10.67 | 2.87 | 0.39 | 0.64 |
EPS (Diluted) | 12.95 | 10.67 | 2.87 | 0.39 | 0.64 |
EPS Growth | 21.37% | 272.24% | 631.22% | -38.90% | 34.11% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -60.35 | -36.91 | -23.13 | -10.58 | - |
Free Cash Flow Per Share | -6.63 | -4.02 | -2.52 | -1.15 | - |
Gross Margin | 59.45% | 46.79% | 55.79% | 28.70% | 20.94% |
Operating Margin | 42.94% | 37.94% | 29.69% | 7.48% | 7.37% |
Profit Margin | 27.32% | 25.64% | 17.26% | 2.22% | 2.77% |
Free Cash Flow Margin | -14.00% | -9.66% | -15.17% | -6.52% | - |
EBITDA | 196.74 | 154.97 | 56.38 | 17.1 | 18.93 |
EBITDA Margin | 45.63% | 40.57% | 36.97% | 10.54% | 8.92% |
D&A For EBITDA | 11.63 | 10.05 | 11.1 | 4.97 | 3.28 |
EBIT | 185.1 | 144.92 | 45.28 | 12.14 | 15.65 |
EBIT Margin | 42.94% | 37.94% | 29.69% | 7.48% | 7.37% |
Effective Tax Rate | 26.86% | 25.47% | 26.28% | 26.21% | 26.13% |
Revenue as Reported | 431.13 | 383.25 | 153.44 | 162.77 | 214.37 |